This clinical trial is testing a medication called hydroxychloroquine (HCQ) to assess safety and effectiveness in people at risk of developing T1D. The study is enrolling people with T1D autoantibodies confirmed by screening, to see if HCQ can prevent T1D developing. HCQ is used as a treatment for malaria, lupus, and rheumatoid arthritis. It has […]
Harmful patterns of insulin resistance in the muscle and liver may be an explanation for increased cardiovascular disease in T1D. The INTIMET study is a detailed investigation of insulin resistance in T1D and will test if metformin can improve insulin action in muscle and the liver. Participants will be asked to take metformin (or placebo […]
Cell Care is partnering with The Children’s Hospital at Westmead, New South Wales, in a world–first study investigating the potential of cord blood to prevent or delay the onset of type 1 diabetes in children at high risk of developing the disease. The CORD study has been approved by the Sydney Children’s Hospitals Network Human […]
This clinical trial is investigating whether fenofibrate, a drug used to lower cholesterol, can slow or reverse eye damage in adults with type 1 diabetes. Fenofibrate has been shown to slow eye damage in type 2 diabetes, and researchers are now investigating whether the same effect will be seen in T1D. This study has been […]
This study is testing whether a new tablet can help to treat kidney disease in people with T1D. This tablet blocks a key component of the pathway responsible for the oxidative stress that damages kidneys. Participants in this clinical trial will attend 10 study visits over 56 weeks. This study has been approved by the […]
Family members of people with T1D are at increased risk of developing the disease themselves. Type1Screen is a free screening service available to any family member of a person with T1D, that can find out a person’s risk of developing T1D. Those at increased risk will be offered the opportunity to enrol in trials of […]
Our researchers are looking for young people with type 1 diabetes with a HbA1c above 9% to be involved in a clinical trial of a new advanced hybrid closed-loop system. We want to see if using the closed-loop insulin delivery system will improve time in range and HbA1c in this group.
